TY - JOUR
T1 - Predicting BRAF V600E mutation in glioblastoma
T2 - utility of radiographic features
AU - Natsumeda, Manabu
AU - Chang, Michael
AU - Gabdulkhaev, Ramil
AU - Takahashi, Haruhiko
AU - Tsukamoto, Yoshihiro
AU - Kanemaru, Yu
AU - Okada, Masayasu
AU - Oishi, Makoto
AU - Okamoto, Kouichirou
AU - Rodriguez, Fausto J.
AU - Kakita, Akiyoshi
AU - Fujii, Yukihiko
AU - Schreck, Karisa C.
N1 - Funding Information:
The authors would like to acknowledge Shingo Nigorikawa and Takeyoshi Eda for advice and technical assistance on molecular analysis. This project was partly funded by Niigata Brain Research Institute Global Collaborative Research Project for FY2020 to F.J.R and Japan Society for Promotion of Science (JSPS) Grant 19K09476 to M.N. This project was also funded by the American Academy of Neurology Clinical Research Training Scholarship and the Maryland Cigarette Restitution Fund award to K.C.S.
Publisher Copyright:
© 2021, The Japan Society of Brain Tumor Pathology.
PY - 2021/7
Y1 - 2021/7
N2 - Detection of BRAF V600E mutation in glioblastomas (GBMs) is important because of potential therapeutic implications. Still, the relative paucity of these mutations makes molecular detection in all GBMs controversial. In the present study, we analyzed clinical, radiographic and pathologic features of 12 BRAF V600E-mutant GBMs and 12 matched controls from 2 institutions. We found that a majority of BRAF V600E-mutant GBMs displayed a combination of well-circumscribed lesions, large cystic components with thin walls and solid cortical component on MRI, but with some overlap with matched BRAF wildtype controls (p = 0.069). BRAF V600E-mutant GBMs were also apt to gross total resection (83% vs 17%, p = 0.016) and morphologically displayed epithelioid features (83% vs 0%, p < 0.0001). Identification of these clinical, radiographic, and pathologic characteristics should prompt testing for BRAF V600E in IDH-wildtype GBM.
AB - Detection of BRAF V600E mutation in glioblastomas (GBMs) is important because of potential therapeutic implications. Still, the relative paucity of these mutations makes molecular detection in all GBMs controversial. In the present study, we analyzed clinical, radiographic and pathologic features of 12 BRAF V600E-mutant GBMs and 12 matched controls from 2 institutions. We found that a majority of BRAF V600E-mutant GBMs displayed a combination of well-circumscribed lesions, large cystic components with thin walls and solid cortical component on MRI, but with some overlap with matched BRAF wildtype controls (p = 0.069). BRAF V600E-mutant GBMs were also apt to gross total resection (83% vs 17%, p = 0.016) and morphologically displayed epithelioid features (83% vs 0%, p < 0.0001). Identification of these clinical, radiographic, and pathologic characteristics should prompt testing for BRAF V600E in IDH-wildtype GBM.
KW - BRAF V600E
KW - Glioblastoma
KW - Pathologic features
KW - Radigraphic features
UR - http://www.scopus.com/inward/record.url?scp=85109295508&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85109295508&partnerID=8YFLogxK
U2 - 10.1007/s10014-021-00407-0
DO - 10.1007/s10014-021-00407-0
M3 - Article
C2 - 34216310
AN - SCOPUS:85109295508
SN - 1433-7398
VL - 38
SP - 228
EP - 233
JO - Brain tumor pathology
JF - Brain tumor pathology
IS - 3
ER -